# FDE Case Study Grid — Revised 6 Studies

## Alignment with Existing Case Study Data

Your Vercel repo already has rich, detailed case studies with full Diagnose → Architect → Engineer → Enable → Impact phases. The portfolio slider should **point to these**, not duplicate them.

---

## Final 6 Case Studies (Portfolio Slider)

| # | Brand | H1 (Title) | H2 (Subtitle) | Existing Data | Slug |
|---|-------|------------|---------------|---------------|------|
| 1 | **Pfizer** | CoCo AI | An industry-first agentic Company Concierge for onboarding, process adherence, and communication flow | `pfizerData.ts`, `cocoData.ts` | `pfizer` / `coco` |
| 2 | **IPG Health** | AI Playbooks | Regulated content systems for global pharmaceutical markets | `ipg-internet.ts`, `publicisData.ts` | `ipg` |
| 3 | **Abbott Alinity** | Advanced Analytics | AI/ML diagnostics platform serving 27,000+ devices globally | `alinity.ts`, `abbottData.ts` | `alinity` |
| 4 | **Pfizer** | Global Content Automation | Human-in-the-loop governance for compliant AI workflows | `pfizerPipelineData.ts`, `colabArchitectData.ts` | `pfizer-pipeline` |
| 5 | **Abbott Libre** | Patient-Critical Systems | Real-time reliability engineering for continuous glucose monitoring | `binaxnow.ts`, `abbottLibre3Data.ts` | `binaxnow` |
| 6 | **Medtronic GI Genius** | Defensible Clinical AI | FDA 510(k) cleared detection with end-to-end data lineage | `medtronicData.ts` | `medtronic` |

---

## Key Metrics From Existing Data

| Case Study | Key Metric 1 | Key Metric 2 | Key Metric 3 |
|------------|--------------|--------------|--------------|
| **CoCo AI** | 200+ users onboarded | 94% training completion | 15 min → <60 sec time-to-answer |
| **AI Playbooks** | $51M portfolio | 13 pharma brands | Zero HIPAA violations |
| **Advanced Analytics** | 27,000 devices | 6 mo → 3 wk deployment | Zero FDA audit findings |
| **Global Content Automation** | 65% faster MLR cycles | 3× asset throughput | $2.08M annual savings |
| **Patient-Critical Systems** | 99.9% uptime | 60% MTTR reduction | HIPAA-compliant data plane |
| **Defensible Clinical AI** | 99.2% accuracy | 40% faster decisions | FDA 510(k) pathway |

---

## H1/H2 Refinement Notes

### Slide 1: Pfizer CoCo AI
- **H1**: CoCo AI
- **H2**: An industry-first agentic Company Concierge for onboarding, process adherence, and communication flow
- **Why**: Positions CoCo as a product, not just a feature. "Industry-first" and "agentic" signal innovation.

### Slide 2: IPG Health AI Playbooks
- **H1**: AI Playbooks  
- **H2**: Regulated content systems for global pharmaceutical markets
- **Why**: "Playbooks" implies reusable, codified knowledge. "Global" and "regulated" signal enterprise scale.

### Slide 3: Abbott Alinity Advanced Analytics
- **H1**: Advanced Analytics
- **H2**: AI/ML diagnostics platform serving 27,000+ devices globally
- **Why**: "27,000+ devices" is a concrete, impressive number. "Globally" signals scale.

### Slide 4: Pfizer Global Content Automation
- **H1**: Global Content Automation
- **H2**: Human-in-the-loop governance for compliant AI workflows
- **Why**: "Human-in-the-loop" is a key differentiator for regulated AI. "Global" signals enterprise.

### Slide 5: Abbott Libre Patient-Critical Systems
- **H1**: Patient-Critical Systems
- **H2**: Real-time reliability engineering for continuous glucose monitoring
- **Why**: "Patient-critical" and "real-time" signal life-or-death stakes. "Continuous glucose monitoring" is specific.

### Slide 6: Medtronic GI Genius Defensible Clinical AI
- **H1**: Defensible Clinical AI
- **H2**: FDA 510(k) cleared detection with end-to-end data lineage
- **Why**: "Defensible" signals audit-ready. "FDA 510(k)" is a concrete regulatory milestone.

---

## Logo Assets Needed

| Brand | Logo File | Status |
|-------|-----------|--------|
| Pfizer | `pfizer-logo.png` | ✅ Have |
| IPG Health | `ipg-logo.png` | ✅ Have |
| Abbott | `abbott-logo.png` | ✅ Have |
| Medtronic | Need white logo | ⚠️ Missing |

---

## Ready to Update?

Run this command to update the portfolio slider with these 6 case studies.
